ALDH2 deficiency is a genetic condition that cripples the body’s ability to break down acetaldehyde, a toxic byproduct of alcohol metabolism, and it affects roughly 540 million people worldwide. The vast majority carry an inherited variant called ALDH2*2 that leaves them with a sluggish or nearly nonfunctional version of the enzyme aldehyde dehydrogenase 2. Most people know it through the so-called “Asian flush,” the facial reddening and rapid heartbeat that follow even a small drink. But the health consequences reach far beyond an uncomfortable evening out, touching cancer risk, heart disease, neurodegeneration, and even how well certain medications work.
How Alcohol Is Normally Processed and Where Things Go Wrong
When you drink alcohol, your liver converts ethanol into acetaldehyde, a compound that is far more toxic than ethanol itself. Under normal circumstances, a mitochondrial enzyme called ALDH2 quickly converts that acetaldehyde into harmless acetic acid, essentially vinegar. The whole process is fast enough that acetaldehyde barely lingers.
In people with ALDH2 deficiency, that second step stalls. The enzyme either works at a fraction of its normal speed or barely works at all, depending on whether someone inherited one copy of the variant gene or two. Acetaldehyde piles up in the blood, and because the molecule is reactive and toxic, it starts causing damage almost immediately. It dilates blood vessels in the face (producing the flush), triggers nausea, and over time, acts as a carcinogen and a source of oxidative stress throughout the body.1PubMed Central. Uncovering newly identified aldehyde dehydrogenase 2 genetic variants that lead to acetaldehyde accumulation after an alcohol challenge
The specific mutation behind most cases is a single amino acid swap at position 504 of the ALDH2 protein, where glutamate is replaced by lysine. This tiny change destabilizes the enzyme’s structure and weakens its ability to bind the cofactor it needs to do its job.2Egyptian Journal of Medical Human Genetics. A comprehensive in silico analysis of structural and functional impacts of natural nonsynonymous SNPs in the ALDH2_HUMAN gene People who are heterozygous (one normal copy, one variant) retain some enzyme activity, while those who are homozygous (two variant copies) retain almost none. Even the heterozygous form cuts enzyme activity dramatically, which is why the flush response appears so reliably.
Who Carries It and Why It Persists
About 40 percent of people of East Asian descent, primarily those with Chinese, Japanese, or Korean ancestry, carry at least one copy of the ALDH2*2 allele.3PubMed Central. Pharmacological recruitment of aldehyde dehydrogenase 3A1 (ALDH3A1) to assist ALDH2 in acetaldehyde and ethanol metabolism in vivo The variant is rare to nonexistent in populations of European, African, or South Asian origin. This extreme geographic concentration has made it a fascinating puzzle for geneticists.
The allele appears to have originated as a random mutation, but its persistence and spread are harder to explain through chance alone. Genetic analyses show unusually high population-differentiation values at the ALDH2 locus, which hints that some kind of selective pressure may have helped maintain it.4PubMed. The evolution and population genetics of the ALDH2 locus: random genetic drift, selection, and low levels of recombination One line of research suggests that environmental factors specific to East Asia, including historical hepatitis B virus exposure and adaptation to high-altitude hypoxia, could have interacted with the allele in ways that offset its obvious disadvantages.5PubMed Central. Origin and Spread of the ALDH2 Glu504Lys Allele The full story is still being assembled, but the takeaway is that the variant’s survival is not just bad luck; something in East Asian population history may have favored or at least tolerated it.
The Alcohol Flush Response
The most visible sign of ALDH2 deficiency is the flush that hits within minutes of drinking: a red face, sometimes spreading to the neck and chest, along with a racing heart, headache, and nausea. An estimated 540 million people worldwide experience this reaction.6PubMed Central. The Alcohol Flush Response These symptoms are a direct result of acetaldehyde flooding the body because ALDH2 cannot clear it fast enough.
Many people treat the flush as a minor annoyance or a social inconvenience. Some push through it, using antihistamines to mask the redness while continuing to drink. This is one of the more dangerous misconceptions around the condition, because the flush is not an allergy or a cosmetic issue. It is a warning that acetaldehyde is accumulating, and suppressing the visible symptoms does nothing to stop the toxic buildup happening internally. Sociocultural pressures in some East Asian communities, where drinking is deeply embedded in business and social rituals, can push people to ignore the signal entirely.7Gastroenterology Nursing. Asian Flushing: Genetic and Sociocultural Factors of Alcoholism Among East Asians
Cancer Risk From Drinking With a Deficient Enzyme
If there is one clinical consequence of ALDH2 deficiency that deserves more public attention, it is cancer. Acetaldehyde is classified as a Group 1 carcinogen, meaning there is strong evidence it causes cancer in humans. For people with ALDH2 deficiency who drink alcohol, the exposure to this carcinogen is dramatically amplified compared with someone whose enzyme works normally.
The strongest evidence involves cancers of the esophagus and head and neck. Studies of East Asian populations consistently show that carriers of the ALDH2*2 allele who drink alcohol face sharply elevated risks for esophageal squamous cell cancer. One large study found that among drinkers, carrying the variant roughly doubled the odds of esophageal cancer compared with drinkers who had the normal enzyme, while no elevated risk appeared in non-drinkers.8PubMed. Alcohol Intake Interacts with Functional Genetic Polymorphisms of Aldehyde Dehydrogenase (ALDH2) and Alcohol Dehydrogenase (ADH) to Increase Esophageal Squamous Cell Cancer Risk That interaction is critical: it is the combination of drinking and having the deficiency that creates the outsized risk, not the gene variant alone.
Gastric cancer follows a similar pattern. Research has shown that ALDH2-deficient individuals who consume alcohol expose their stomach lining to markedly higher concentrations of acetaldehyde than people with the normal enzyme, providing a plausible mechanism for the link between the deficiency and stomach cancer.9PLoS ONE. Effects of ALDH2 Genotype, PPI Treatment and L-Cysteine on Carcinogenic Acetaldehyde in Gastric Juice and Saliva after Intragastric Alcohol Administration Evidence for other cancers, including those of the colon and liver, is building but remains more limited.10PubMed Central. ALDH2 polymorphism and alcohol-related cancers in Asians: a public health perspective
The practical message from the cancer literature is blunt: if you flush when you drink, the safest approach is to drink very little or not at all. Acetaldehyde from even moderate drinking is doing damage that compounds over years, and the standard “moderate drinking” guidelines written for the general population were not designed with ALDH2-deficient individuals in mind.
Cardiovascular Effects Beyond Alcohol
ALDH2 does more than process drinking-related acetaldehyde. The enzyme also clears other toxic aldehydes that build up during oxidative stress, a process that happens throughout the body and accelerates during events like a heart attack. This gives the deficiency a cardiovascular dimension that has nothing to do with whether someone drinks.
During a heart attack, blood flow to part of the heart muscle is cut off and then restored (a sequence called ischemia-reperfusion). That restoration of blood flow paradoxically produces a burst of damaging molecules, including toxic aldehydes. Animal studies have shown that hearts lacking functional ALDH2 suffer substantially larger areas of damage during these events, with worse recovery of heart function afterward.11European Heart Journal. Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial ischaemia/reperfusion injury: role of autophagy paradox and toxic aldehyde More recent work has identified a specific mechanism: ALDH2-deficient hearts show increased formation of neutrophil extracellular traps, a type of immune-system overreaction that worsens tissue damage after the blood supply is restored.12European Heart Journal. Myocardial reperfusion injury exacerbation due to ALDH2 deficiency is mediated by neutrophil extracellular traps and prevented by leukotriene C4 inhibition
Population-level data back up these lab findings. The ALDH2 Glu504Lys variant has been associated with increased risk of cardiovascular disease and stroke in East Asian populations.5PubMed Central. Origin and Spread of the ALDH2 Glu504Lys Allele While lifestyle and other genetic factors play large roles in heart disease, carrying the deficiency appears to add a layer of vulnerability that clinicians treating East Asian patients should factor in.
Why Nitroglycerin Works Differently
One of the more clinically actionable facts about ALDH2 deficiency involves a medication that has been used for heart disease for over a century: nitroglycerin. ALDH2 turns out to be the key enzyme that converts nitroglycerin into its active form, nitric oxide, which relaxes blood vessels and relieves chest pain. If your ALDH2 is impaired, nitroglycerin simply does not work as well.
A study of patients with coronary spastic angina found that those carrying the ALDH2*2 variant had a weaker blood-vessel-dilation response to nitroglycerin at baseline and developed tolerance to the drug faster than patients with normal ALDH2.13Circulation Journal. East Asians Variant Mitochondrial Aldehyde Dehydrogenase 2 Genotype Exacerbates Nitrate Tolerance in Patients With Coronary Spastic Angina For the roughly 8 percent of East Asians who are homozygous for the variant, the drug may be substantially less effective in a cardiac emergency. This is the kind of gene-drug interaction that pharmacogenomic testing could flag ahead of time, potentially steering clinicians toward alternative anti-anginal therapies.
Connections to Neurodegeneration
Toxic aldehydes are not just a problem for the heart and gut. The brain is highly susceptible to oxidative stress, and ALDH2 appears to play a protective role there as well. A growing body of research is exploring links between ALDH2 deficiency and neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease.14PubMed Central. The Role of Mitochondrial Aldehyde Dehydrogenase 2 (ALDH2) in Neuropathology and Neurodegeneration
The logic is consistent with what we see in the heart: when ALDH2 cannot efficiently clear reactive aldehydes like 4-hydroxynonenal (a lipid peroxidation product that accumulates in aging brains), those aldehydes damage proteins and mitochondria in neurons. Whether this translates to a measurably higher risk of dementia for the hundreds of millions of ALDH2-deficient people in East Asia is an open and important question, but the mechanistic evidence is concerning enough to attract serious research attention.
Liver Disease Without a Drop of Alcohol
ALDH2’s role in processing endogenous (internally generated) aldehydes also has implications for liver health. In mouse models, ALDH2 deficiency worsened nonalcoholic steatohepatitis, a form of fatty liver disease driven by diet and metabolism rather than by drinking. The ALDH2-deficient mice showed more liver inflammation, more fat accumulation, and worse intestinal barrier function than their normal counterparts. Intriguingly, the damage was at least partly mediated through the gut: transplanting gut bacteria from the ALDH2-deficient mice into normal mice transferred some of the disease severity, and supplementing with certain probiotic bacteria improved outcomes.15Pharmacological Research. Host ALDH2 deficiency aggravates nonalcoholic steatohepatitis through gut-liver axis
This is early-stage research conducted in animals, so direct clinical recommendations would be premature. But it does suggest that ALDH2-deficient individuals may want to pay extra attention to metabolic health: maintaining a healthy weight, avoiding diets high in processed fats and sugars, and being aware that their livers may have less margin for error even without alcohol in the picture.
Screening for ALDH2 Status
You might wonder whether you or someone you know is ALDH2-deficient. There are a few ways to find out, ranging from high-tech to remarkably low-tech.
The gold standard is a genetic test, typically looking for the rs671 variant through a blood or saliva sample. These tests are increasingly available through clinical labs and direct-to-consumer genotyping services. But decades before affordable genotyping arrived, researchers validated a simple alternative: the ethanol patch test. A small gauze pad soaked in ethanol is taped to the inner arm for about 15 to 20 minutes. If the skin underneath turns red, the person is likely a carrier of ALDH2*2.16PubMed. Screening for acetaldehyde dehydrogenase 2 genotype in alcohol-induced asthma by using the ethanol patch test Researchers have even refined this approach using smartphone cameras and color-analysis software, achieving sensitivity around 86 percent and specificity above 96 percent for detecting the mutation.17PubMed. Alcohol patch test with hue-saturation-value model analysis predicts ALDH2 genetic polymorphism
For clinical settings in East Asia, routine ALDH2 genotyping before prescribing nitroglycerin or counseling patients about alcohol-related cancer risk could catch people who would otherwise learn about their deficiency only through unpleasant experience. Outside of East Asian populations, routine screening is harder to justify given the allele’s rarity, but individual testing makes sense for anyone of East Asian heritage, especially before starting certain medications.
Experimental Therapies and Enzyme Activators
The most exciting therapeutic development in the ALDH2 field is a small molecule called Alda-1. Identified through a high-throughput screening process, Alda-1 acts as a chemical chaperone that stabilizes the ALDH2 enzyme and boosts its activity. In animal studies, administering Alda-1 before an induced heart attack reduced the area of damaged heart tissue by about 60 percent. Critically, Alda-1 was especially effective at restoring function to the ALDH2*2 mutant enzyme, the very form carried by hundreds of millions of people in East Asia.18PubMed Central. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart
Alda-1 is not yet approved for clinical use, and translating animal results into proven human therapies is always uncertain. But the concept of pharmacologically rescuing a defective enzyme, rather than trying to replace it or work around it, is compelling. If the approach pans out, it could address not just heart damage but potentially some of the cancer risk, neurodegeneration, and metabolic vulnerability linked to the deficiency.
A separate line of investigation has looked at nutritional supplements. A small trial tested a supplement formulation in ALDH2-deficient subjects and found that after 28 days, average blood acetaldehyde levels measured 20 minutes after drinking fell from about 0.91 mg/dL to 0.71 mg/dL, a statistically significant reduction. Liver enzyme markers also improved over the same period.19PubMed Central. Effects of “Essential AD2” Supplement on Blood Acetaldehyde Levels in Individuals Who Have Aldehyde Dehydrogenase (ALDH2) Deficiency This is a single small study, and a roughly 22 percent drop in acetaldehyde is a long way from normalizing levels to what someone with a fully functional enzyme would have. Still, for people who do drink, even partial acetaldehyde reduction could be meaningful over time.
An Unexpected Role in Pain and Anesthesia
ALDH2 is not limited to the liver. It is expressed in tissues throughout the body, including the spinal cord, where recent research has revealed a surprising connection to pain processing. In mouse experiments, astrocytes (support cells in the spinal cord) use ALDH2 to convert ethanol-derived acetaldehyde into acetate, which in turn stimulates the release of the inhibitory neurotransmitter GABA. This GABA release contributes to alcohol’s pain-numbing effects. When researchers knocked out ALDH2 specifically in spinal astrocytes, alcohol’s analgesic effect vanished while its effects on motor function remained unchanged.20British Journal of Anaesthesia. Spinal astrocyte aldehyde dehydrogenase-2 mediates ethanol metabolism and analgesia in mice
This finding is still in animal models, but it opens a line of questioning about whether ALDH2-deficient people process pain differently or respond differently to certain anesthetic agents that share biochemical pathways with alcohol metabolism. Anesthesiologists working with East Asian patient populations may eventually need to account for ALDH2 status when planning sedation protocols, though that level of precision is not yet part of standard practice.
Beyond the rs671 Variant
Almost all research and public awareness of ALDH2 deficiency has focused on the rs671 variant, for obvious reasons: it affects hundreds of millions of people and has clear clinical consequences. But the ALDH2 gene can harbor other natural variations that impair enzyme function. Researchers have used computational modeling to screen nonsynonymous mutations across the ALDH2 gene and identified additional variants, like E487K, that significantly reduce the enzyme’s ability to bind its cofactor and destabilize its overall structure.2Egyptian Journal of Medical Human Genetics. A comprehensive in silico analysis of structural and functional impacts of natural nonsynonymous SNPs in the ALDH2_HUMAN gene Separately, clinical researchers have found that some individuals show the classic acetaldehyde-accumulation pattern after drinking despite not carrying rs671, suggesting that newly identified rare variants in ALDH2 can produce functionally similar deficiencies.1PubMed Central. Uncovering newly identified aldehyde dehydrogenase 2 genetic variants that lead to acetaldehyde accumulation after an alcohol challenge
This means that ALDH2 deficiency is not exclusively an East Asian phenomenon in the strictest sense. While the dominant rs671 variant is, rare mutations elsewhere in the gene could produce similar enzyme impairments in individuals of any background. If you flush severely but genetic testing for rs671 comes back negative, it may be worth looking deeper at the ALDH2 gene itself.
What Clinicians in Non-Asian Settings Often Miss
In Western medical systems, ALDH2 deficiency rarely appears on the clinical radar. It is not included in standard metabolic panels, it is not flagged in most electronic health record systems, and many physicians outside of East Asia have never been taught about it. The result is a knowledge gap that can have real consequences for patients of East Asian descent living in Western countries.
Consider the nitroglycerin issue. A patient presenting in an emergency department with chest pain who happens to be ALDH2-deficient may receive nitroglycerin as a first-line treatment and get less relief than expected, potentially leading to confusion about the severity of their condition. Or consider the cancer counseling gap: a patient who mentions that alcohol makes them flush might be told it is “just an intolerance” without any discussion of the elevated cancer risk that accompanies continued drinking. Screening with even a simple patch test, followed by targeted counseling, could meaningfully change outcomes for these patients.
As pharmacogenomics becomes more integrated into mainstream medicine, ALDH2 genotyping is a natural candidate for inclusion in pre-treatment panels, at minimum for patients being prescribed nitrate-based cardiac drugs. For cancer prevention, public health campaigns in East Asian communities that clearly link the flush response to carcinogen exposure, rather than framing it as a harmless quirk, could shift behavior more effectively than generic warnings about alcohol consumption.